For biotech, Russian invasion of Ukraine threatens to upend a slew of early-stage R&D projects

Jason Mast

Editor

The global implications of Russia’s invasion of Ukraine won’t become clear for weeks, if not years, but the crisis is already causing consternation among biotech …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

For biotech, Russian invasion of Ukraine threatens to upend a slew of early-stage R&D projects

Jason Mast

Editor

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

CBER's deputy director departs as staff shakeup continues

Will CRISPR matter?

FDA approves first drug to treat ultra-rare lipid storage disease

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

For biotech, Russ­ian in­va­sion of Ukraine threat­ens to up­end a slew of ear­ly-stage R&D projects

Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

For biotech, Russian invasion of Ukraine threatens to upend a slew of early-stage R&D projects